Members of the lab attended this year’s ILC symposium in Leuven, Belgium.
Another successful participation in the annual Susan G. Komen More Than Pink Walk is in the books! The lab also hosted a table for information on the “Hope for OTHERS” tissue donation program.
The Lee/Oesterreich lab is delighted to receive two grant awards from the Breast Cancer Alliance (http://breastcanceralliance.org/).
The BCA selected to fund our projects entitled ‘Therapeutic targeting of novel pathways in breast cancer brain metastases’ and ‘Understanding the importance of ESR1 fusion genes in metastatic breast cancer”. The grants provide one year of funding support for these exciting projects.
We are very grateful for the funding to continue our quest to better understand and target endocrine resistant breast cancer.
Dr. Adrian Lee was recently interviewed for the “Do-Goodery Podcast: The Cancer Episode” to, as described by their website, “discuss what a jerk Cancer is. We Take Astro 101, learn about new weapons in the fight against Cancer, and how to support those who’ve received a Cancer diagnosis.”
Listen here:
Behold! The #Cancer Episode of The Do-Goodery Podcast!@PittTweet‘s Dr. Adrian Lee, a leading Cancer researcher, on the new weapons we have to fight it in this Golden Era of Cancer research.@OurClubhousePA on how to support those affected by Cancer.https://t.co/5OmJlL9ciw
— Rocco DeMaro (@RoccoDeMaro) November 12, 2018
Steffi meets with members of LBCA advocacy group (https://lobularbreastcancer.org/), and discusses progress and challenges for ILC research at the Northwest Metastatic Breast Cancer Conference (NWMBCC).
The presentation was live streamed, and can be seen here: https://www.facebook.com/lobularbreastcanceralliance/videos/553742191751845/.
Of note, Leigh Pate, founder of LBCA, receives the Beth Caldwell Breakthrough Leadership award.
We provide evidence that loss of E-cadherin hyperactivates the IGF1R pathway and increases sensitivity to IGF1R/InsR targeted therapy, thus identifying the IGF1R pathway as a potential novel target in E-cadherin–deficient breast cancers such as invasive lobular cancer.
Congratulation Dr. Nilgun Tasdemir and coauthors for their new publication generating an invaluable resource for lobular breast cancer research. Comprehensive characterization of ILC models.
Our latest paper focused on lobular breast cancer is now available. Role for SREBP1 and other regulators of fatty acid and cholesterol synthesis in invasive lobular breast cancer.
